[{"id":"ad1d963e-b163-427e-be70-2d37437a6605","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471841","created_at":"2026-03-28T01:44:38.203Z","updated_at":"2026-03-28T01:44:38.203Z","phase":"Phase 2","brief_title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","source_id_and_acronym":"NCT07471841","lead_sponsor":"Timothy Pardee","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2026-03-13"},{"id":"8ecfd71e-09dc-439f-af05-bbb7a6382e68","acronym":"","url":"https://clinicaltrials.gov/study/NCT07130695","created_at":"2025-08-23T13:32:09.751Z","updated_at":"2025-08-23T13:32:09.751Z","phase":"Phase 1","brief_title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","source_id_and_acronym":"NCT07130695","lead_sponsor":"Virginia Commonwealth University","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/31/2025","start_date":" 10/31/2025","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-08-19"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"7f66ca0f-1441-4209-9937-3fd50a8da5b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04242849","created_at":"2021-01-18T20:37:36.734Z","updated_at":"2025-02-25T13:40:03.346Z","phase":"","brief_title":"IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up","source_id_and_acronym":"NCT04242849","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 354","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 12/27/2019","primary_completion_date":" 12/27/2019","study_txt":" Completion: 01/16/2020","study_completion_date":" 01/16/2020","last_update_posted":"2025-02-21"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"5f8b072a-82e7-4058-ac66-89f1f2f42c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576117","created_at":"2021-01-18T21:50:45.604Z","updated_at":"2025-02-25T16:32:16.258Z","phase":"Phase 3","brief_title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT04576117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1 • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E","tags":["BRAF • IDH1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-07"},{"id":"c5be4f65-abfd-49b2-9e6b-92e20f00da7f","acronym":"STING","url":"https://clinicaltrials.gov/study/NCT03048084","created_at":"2021-01-18T15:00:39.333Z","updated_at":"2025-02-25T16:51:48.926Z","phase":"Phase 4","brief_title":"Seizure Treatment in Glioma","source_id_and_acronym":"NCT03048084 - STING","lead_sponsor":"Leiden University Medical Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-04"},{"id":"066ab336-a212-45de-9f07-3f558dc780e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02746081","created_at":"2021-01-18T13:27:15.549Z","updated_at":"2025-02-25T17:08:45.816Z","phase":"Phase 1","brief_title":"Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors","source_id_and_acronym":"NCT02746081","lead_sponsor":"Bayer","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY1436032"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 12/03/2024","study_completion_date":" 12/03/2024","last_update_posted":"2024-12-18"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"6e3accdd-5a43-478f-a02d-784bf9cd8ce5","acronym":"NCI-2018-00876","url":"https://clinicaltrials.gov/study/NCT03528642","created_at":"2021-01-18T17:22:22.349Z","updated_at":"2024-07-02T16:34:37.431Z","phase":"Phase 1","brief_title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","source_id_and_acronym":"NCT03528642 - NCI-2018-00876","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"83fb8ec7-113b-40ac-abe0-a62e72250dc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03423628","created_at":"2021-01-18T16:53:18.718Z","updated_at":"2024-07-02T16:35:02.625Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","source_id_and_acronym":"NCT03423628","lead_sponsor":"AstraZeneca","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD1390"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 04/22/2026","primary_completion_date":" 04/22/2026","study_txt":" Completion: 04/22/2026","study_completion_date":" 04/22/2026","last_update_posted":"2024-05-20"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"67354b23-56a9-47e7-b780-039f1a9df99b","acronym":"IDIOME-STUDY","url":"https://clinicaltrials.gov/study/NCT03503409","created_at":"2021-01-18T17:14:52.332Z","updated_at":"2024-07-02T16:35:08.621Z","phase":"Phase 2","brief_title":"IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome","source_id_and_acronym":"NCT03503409 - IDIOME-STUDY","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2024-04-19"},{"id":"07a51dc9-114c-48cd-acba-f59680179bb5","acronym":"INNATE","url":"https://clinicaltrials.gov/study/NCT04669899","created_at":"2021-07-23T15:52:37.047Z","updated_at":"2024-07-02T16:35:10.864Z","phase":"Phase 1/2","brief_title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04669899 - INNATE","lead_sponsor":"Jounce Therapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK • IDH1 • FGFR","pipe":" | ","alterations":" EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation","tags":["EGFR • PD-L1 • ALK • IDH1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimivalimab (JTX-4014) • polzastobart (JTX-8064)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 11/28/2023","study_completion_date":" 11/28/2023","last_update_posted":"2024-04-09"},{"id":"fca31f0b-440e-4612-89e8-eec4d5639d00","acronym":"AGILE","url":"https://clinicaltrials.gov/study/NCT03173248","created_at":"2021-01-18T15:38:46.635Z","updated_at":"2024-07-02T16:35:11.233Z","phase":"Phase 3","brief_title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","source_id_and_acronym":"NCT03173248 - AGILE","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-05"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"07f72434-f6fa-47b7-ba9f-45d495429259","acronym":"","url":"https://clinicaltrials.gov/study/NCT01358058","created_at":"2021-01-18T05:33:17.210Z","updated_at":"2024-07-02T16:35:12.677Z","phase":"","brief_title":"Proton Radiation Therapy for Gliomas","source_id_and_acronym":"NCT01358058","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-27"},{"id":"5a752d2a-ae6c-4568-9964-397e60ac09c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02481154","created_at":"2021-01-18T11:56:50.778Z","updated_at":"2024-07-02T16:35:13.092Z","phase":"Phase 1","brief_title":"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02481154","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 10/17/2022","primary_completion_date":" 10/17/2022","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-03-22"},{"id":"8b030438-7eb9-4387-b341-1cc25b72dae1","acronym":"ViCToRy","url":"https://clinicaltrials.gov/study/NCT05609994","created_at":"2022-11-08T14:56:43.419Z","updated_at":"2024-07-02T16:35:13.515Z","phase":"Phase 1","brief_title":"ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas","source_id_and_acronym":"NCT05609994 - ViCToRy","lead_sponsor":"Katy Peters, MD, PhD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-21"},{"id":"ab51b5e6-0963-4336-9f95-fd4b7d31aa37","acronym":"POLO","url":"https://clinicaltrials.gov/study/NCT04702581","created_at":"2021-01-19T20:50:53.653Z","updated_at":"2024-07-02T16:35:14.234Z","phase":"Phase 3","brief_title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","source_id_and_acronym":"NCT04702581 - POLO","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-18"},{"id":"95731383-c806-4e36-ace1-c94c54c5626b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564821","created_at":"2021-01-18T17:32:33.230Z","updated_at":"2024-07-02T16:35:15.543Z","phase":"Phase 1","brief_title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03564821","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1 • HLA-B","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 05/22/2022","primary_completion_date":" 05/22/2022","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2024-03-08"}]